uniQure N.V. (QURE)

followers · Follow

Sector:

HEALTH CARE

Industry:

BIOTECHNOLOGY & LIFE SCIENCES

SIC:

PHARMACEUTICAL PREPARATIONS

CEO:

Matthew C. Kapusta

Employees:

500

PAASHEUVELWEG 25A, AMSTERDAM, P7, 1105 BP

1-339-970-7000

uniqure.com

uniQure N.V. engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in clinical study for Huntington's disease.

	All 13F Filers	Prior	Change	Hedge Funds ¹	Prior	Change

uniQure N.V. YCharts
Yahoo! Finance	finviz
SEC Web Site	SEC DEF 14A Filings

Shareholders (13F, 13D/G)

Current Mutual Fund/ETF Holders

Active 13D/G Filings

SEC Filings

Insiders

Short Positions

Congress

Proposed Sales

Comments and Updates

To Excel | To CSV | To TSV

Investor	History	Shares Held or Principal Amt	Market Value	% of Portfolio	Previous % of Portfolio	Rank	Change in Shares	% Ownership	Qtr 1st Owned	Est. Avg Price	Source	Source Date	Date Reported
No data available